Skip to main content

Advertisement

SpringerLink
Log in

Expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) associated with poor survival in gastric cancer

  • Original Article
  • Published:
Tumor Biology

Abstract

Altered expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) was associated with human carcinogenesis and progression. This study assessed eIF5A-2 expression in gastric cancer tissues for association with clinicopathological parameters and survival of patients. A total of 436 gastric cancer tissues and 92 normal mucosal blocks were collected for construction of tissue microarrays and immunohistochemical assessment of eIF5A-2 expression. The data were statistically analyzed for association with clinicopathological factors and survival of patients. Immunohistochemical data showed that eIF5A-2 protein was highly expressed in gastric cancer tissues (p < 0.001). Upregulated expression of eIF5A-2 protein was associated with tumor Lauren classification, size, location, invasion, TNM stages, and lymph node and distant metastases. The 3- and 5-year cumulative survival rates of these 436 patients were 88.5 and 58.1 %, respectively. In contrast, the mean survival time of patients with increased tumor eIF5A-2 was 30.22 ± 1.23 vs. 51.29 ± 0.86 months for those with low tumor eIF5A-2 (p < 0.001). Multivariate analysis showed that eIF5A-2 expression and related tumor parameters were independent indicators of overall survival in gastric cancer patients. In conclusion, the current study indicates that overexpression of eIF5A-2 protein was associated with poor overall survival of gastric cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer. 2004;101(12):2843–50. doi:10.1002/cncr.20666.

    Article  PubMed  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.

    Article  PubMed  Google Scholar 

  3. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 2014 WCR.

  5. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635–49. doi:10.3748/wjg.v20.i7.1635.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Ann Oncol. 2003;14 Suppl 5:v61–118.

    Article  PubMed  Google Scholar 

  7. Grabsch HI, Tan P. Gastric cancer pathology and underlying molecular mechanisms. Dig Surg. 2013;30(2):150–8. doi:10.1159/000350876.

    Article  CAS  PubMed  Google Scholar 

  8. Li J, Davies BR, Han S, Zhou M, Bai Y, Zhang J, et al. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. J Transl Med. 2013;11:241. doi:10.1186/1479-5876-11-241.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Schnier J, Schwelberger HG, Smit-McBride Z, Kang HA, Hershey JW. Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast Saccharomyces cerevisiae. Mol Cell Biol. 1991;11(6):3105–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Park MH. The post-translational synthesis of a polyamine-derived amino acid, hypusine, in the eukaryotic translation initiation factor 5A (eIF5A). J Biochem. 2006;139(2):161–9. doi:10.1093/jb/mvj034.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Clement PM, Johansson HE, Wolff EC, Park MH. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. Febs J. 2006;273(6):1102–14. doi:10.1111/j.1742-4658.2006.05135.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Clement PM, Henderson CA, Jenkins ZA, Smit-McBride Z, Wolff EC, Hershey JW, et al. Identification and characterization of eukaryotic initiation factor 5A-2. Eur J Biochem. 2003;270(21):4254–63.

    Article  CAS  PubMed  Google Scholar 

  13. Jenkins ZA, Haag PG, Johansson HE. Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics. 2001;71(1):101–9. doi:10.1006/geno.2000.6418.

    Article  CAS  PubMed  Google Scholar 

  14. Chen W, Luo JH, Hua WF, Zhou FJ, Lin MC, Kung HF, et al. Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Epidemiol Biomarkers Prev. 2009;18(2):400–8. doi:10.1158/1055-9965.EPI-08-0754.

    Article  CAS  PubMed  Google Scholar 

  15. Gosslau A, Jao DL, Butler R, Liu AY, Chen KY. Thermal killing of human colon cancer cells is associated with the loss of eukaryotic initiation factor 5A. J Cell Physiol. 2009;219(2):485–93. doi:10.1002/jcp.21696.

    Article  CAS  PubMed  Google Scholar 

  16. Guan XY, Sham JS, Tang TC, Fang Y, Huo KK, Yang JM. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res. 2001;61(9):3806–9.

    CAS  PubMed  Google Scholar 

  17. Lee HS, Cho SB, Lee HE, Kim MA, Kim JH, do Park J, et al. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res. 2007;13(14):4154–63. doi:10.1158/1078-0432.CCR-07-0173.

    Article  CAS  PubMed  Google Scholar 

  18. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003;200(1):39–46. doi:10.1002/path.1288.

    Article  CAS  PubMed  Google Scholar 

  19. Geisler SA, Olshan AF, Weissler MC, Cai J, Funkhouser WK, Smith J, et al. p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res. 2002;8(11):3445–53.

    CAS  PubMed  Google Scholar 

  20. Song LB, Liao WT, Mai HQ, Zhang HZ, Zhang L, Li MZ, et al. The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett. 2006;242(2):258–65. doi:10.1016/j.canlet.2005.11.013.

    Article  CAS  PubMed  Google Scholar 

  21. Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med. 2014;16, e1. doi:10.1017/erm.2013.16.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 2003;4(8):657–65. doi:10.1038/nrm1175.

    Article  PubMed  Google Scholar 

  23. Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, et al. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget. 2013;4(1):9–17.

    PubMed  Google Scholar 

  24. Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, et al. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology. 2010;51(4):1255–63. doi:10.1002/hep.23451.

    Article  CAS  PubMed  Google Scholar 

  25. Hu L, Wen JM, Sham JS, Wang W, Xie D, Tjia WM, et al. Establishment of cell lines from a primary hepatocellular carcinoma and its metastatis. Cancer Genet Cytogenet. 2004;148(1):80–4.

    Article  CAS  PubMed  Google Scholar 

  26. Petersen I, Bujard M, Petersen S, Wolf G, Goeze A, Schwendel A, et al. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res. 1997;57(12):2331–5.

    CAS  PubMed  Google Scholar 

  27. Shek FH, Fatima S, Lee NP. Implications of the use of eukaryotic translation initiation factor 5A (eIF5A) for prognosis and treatment of hepatocellular carcinoma. Int J Hepatol. 2012;2012:760928. doi:10.1155/2012/760928.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Xie D, Ma NF, Pan ZZ, Wu HX, Liu YD, Wu GQ, et al. Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma. Hum Pathol. 2008;39(1):80–6. doi:10.1016/j.humpath.2007.05.011.

    Article  CAS  PubMed  Google Scholar 

  29. Yang GF, Xie D, Liu JH, Luo JH, Li LJ, Hua WF, et al. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecol Oncol. 2009;112(2):314–8. doi:10.1016/j.ygyno.2008.10.024.

    Article  CAS  PubMed  Google Scholar 

  30. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008;135(5):852–64. doi:10.1016/j.cell.2008.09.061.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Lee NP, Tsang FH, Shek FH, Mao M, Dai H, Zhang C, et al. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Int J Cancer. 2010;127(4):968–76. doi:10.1002/ijc.25100.

    CAS  PubMed  Google Scholar 

  32. He LR, Zhao HY, Li BK, Liu YH, Liu MZ, Guan XY, et al. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients. Int J Cancer. 2011;129(1):143–50. doi:10.1002/ijc.25669.

    Article  CAS  PubMed  Google Scholar 

  33. Marchet A, Mocellin S, Belluco C, Ambrosi A, DeMarchi F, Mammano E, et al. Gene expression profile of primary gastric cancer: towards the prediction of lymph node status. Ann Surg Oncol. 2007;14(3):1058–64. doi:10.1245/s10434-006-9090-0.

    Article  PubMed  Google Scholar 

  34. Xu GD, Shi XB, Sun LB, Zhou QY, Zheng DW, Shi HS, et al. Down-regulation of eIF5A-2 prevents epithelial-mesenchymal transition in non-small-cell lung cancer cells. J Zhejiang Univ Sci B. 2013;14(6):460–7. doi:10.1631/jzus.B1200200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ, Liao YJ, et al. Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response tochemotherapy via regulation of matrix metalloproteinase 2 expression. Oncotarget. 2014;5(16):6716–33.

    Article  Google Scholar 

  36. Khosravi S, Wong RP, Ardekani GS, Zhang G, Martinka M, Ong CJ, et al. Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion. Br J Cancer. 2014;110(2):399–408. doi:10.1038/bjc.2013.688.

    Article  CAS  PubMed  Google Scholar 

  37. Wei JH, Cao JZ, Zhang D, Liao B, Zhong WM, Lu J, et al. EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cellaggressiveness in vitro and in vivo. Br J Cancer. 2014;110(7):1767–77. doi:10.1038/bjc.2014.52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Chen M, Huang JD, Deng HK, Dong S, Deng W, Tsang SL,et al. Overexpression of eIF-5A2 in mice causes accelerated organismal aging by increasing chromosome instability. BMC Cancer. 2011;11:199. doi:10.1186/1471-2407-11-199.

Download references

Acknowledgments

This study was supported in part by grants from the Zhejiang Provincial Department of Science and Technology Research Foundation (no. 2008C33040) and the Zhejiang Provincial Medical Science Research Foundation (no. 2007A013). The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; and in the decision to publish the results.

Compliance with ethical standards

ᅟ

Conflicts of interest

None

Research involving human participants and/or animals

This study was approved by the Ethical Committee of Zhejiang Provincial People’s Hospital.

Informed consent

Written informed consent for use of the resected samples was obtained from each patient.

Author information

Authors and Affiliations

  1. Wenzhou Medical University, Wenzhou, China

    Qiong Yang & Zaiyuan Ye

  2. Department of Gastrointestinal Surgery, Zhejiang Provincial People’s Hospital, Hangzhou, China

    Qiong Yang, Zaiyuan Ye, Qi Zhang, Zhongsheng Zhao & Hongjun Yuan

Authors
  1. Qiong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zaiyuan Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhongsheng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongjun Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zaiyuan Ye or Zhongsheng Zhao.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, Q., Ye, Z., Zhang, Q. et al. Expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) associated with poor survival in gastric cancer. Tumor Biol. 37, 1189–1195 (2016). https://doi.org/10.1007/s13277-015-3894-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3894-0

Keywords

Search

Navigation